LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.49 per share and revenue of $55.99 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.
LeMaitre Vascular Price Performance
NASDAQ:LMAT opened at $104.00 on Wednesday. The firm has a 50-day moving average of $96.23 and a two-hundred day moving average of $94.42. The stock has a market cap of $2.34 billion, a P/E ratio of 56.83, a PEG ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a 1-year low of $61.09 and a 1-year high of $109.58.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Barrington Research upped their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. Oppenheimer restated an “outperform” rating and issued a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average target price of $94.63.
About LeMaitre Vascular
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Featured Articles
- Five stocks we like better than LeMaitre Vascular
- 3 Small Caps With Big Return Potential
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- The Basics of Support and Resistance
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.